Lucatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 146 kg/mol |
  (what is this?) (verify) | |
Lucatumumab (CHIR 12.12 or HCD122)[1] is a human monoclonal antibody against CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.[3]
It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.[6][7][8] Novartis took over the project when it acquired Chiron in 2005.[9][10]
In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.[11]
Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.[1]
References
- ^ a b c Hassan SB, Sørensen JF, Olsen BN, Pedersen AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials". Immunopharmacology and Immunotoxicology. 36 (2): 96–104. doi:10.3109/08923973.2014.890626. PMID 24555495.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ^ "Lucatumumab". AdisInsight. Retrieved 20 February 2017.
- ^ "Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference". XOMA and Chiron vis Businesswire. December 2, 2004.
- ^ Weng, Wen-Kai; Tong, Xia; Luqman, Mohammad; Levy, Ronald (16 November 2004). "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma". Blood. 104 (11): 3279. ISSN 0006-4971.
{{cite journal}}: Unknown parameter|name-list-format=ignored (|name-list-style=suggested) (help) - ^ "Chiron and Xoma in MAb deal - Pharmaceutical industry news". The Pharma Letter. March 8, 2004.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
- ^ "Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar.
- ^ "Exhibit 10.2 Amended Research, Development and Commercialization Agreement". www.sec.gov. Xoma via SEC Edgar. May 26, 2005.
- ^ Tansey, Bernadette (November 1, 2005). "Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion". San Francisco Chronicle.
{{cite news}}: Unknown parameter|name-list-format=ignored (|name-list-style=suggested) (help) - ^ "Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008.
- ^ "Lucatumumab". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. Retrieved 20 February 2017.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |